Abiraterone decanoate - Propella Therapeutics
Alternative Names: ASP-5541; PRL-02Latest Information Update: 19 Oct 2025
At a glance
- Originator Propella Therapeutics
- Class Antineoplastics; Cyclopentanes; Esters; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors; Testosterone antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 19 Oct 2025 Chemical structure information added.
- 19 Jun 2025 Phase-II clinical trials in Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IM) (NCT07005154)
- 19 Jun 2025 Phase-II clinical trials in Prostate cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in Japan (IM) (NCT07005154)